Prospective Multi-Center Study for Clinical Validation of the Molecular-Based GenePOC CDiff System for the Detection of Toxin B Gene From Toxigenic Clostridium Difficile Strains in Unformed (Soft or Liquid) Human Stool Specimens
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Clostridium Difficile Infection
- Sponsor
- Meridian Bioscience, Inc.
- Enrollment
- 2461
- Locations
- 7
- Primary Endpoint
- Performance Characteristics : Clinical Sensitivity (True Positive Rate) and Clinical Specificity (True Negative Rate) in Comparison to the Reference Method
- Status
- Completed
- Last Updated
- 5 years ago
Overview
Brief Summary
The primary purpose of this clinical investigation is to verify the performance of the GenePOC CDiff test on the GenePOC instrument. This will be achieved by comparing the GenePOC CDiff test to the Toxigenic Culture (TC) and cell cytotoxicity neutralisation assay (CCNA), a conventional method considered as gold standard for detection of toxigenic Clostridium difficile in stool specimens.
Detailed Description
The GenePOC CDiff test performed on the GenePOC™ instrument is a qualitative in vitro diagnostic (IVD) test that utilizes automated sample preparation and real-time polymerase chain reaction (rtPCR) to detect the toxin B (tcdB) gene of toxigenic Clostridium difficile (C. difficile) in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The GenePOC CDiff system comprises the GenePOC instrument and the GenePOC CDiff test, which consists of: 1. Transfer Loop (TL) 2. CDiff disposable microfluidic cartridges (PIE) (described in this document as PIEs because of the shape of the cartridge) 3. CDiff Sample Buffer Tube (SBT) 4. Disposable Transfer Tool (DTT). The GenePOC Instrument is fully automated and integrates sample lysis, dilution, amplification and detection of the target sequence in complex samples using real-time Polymerase chain reaction (rtPCR). User intervention is only required for discharging the patient sample into the SBT (sample Buffer Tube), transferring the sample into the PIE and for loading/unloading the PIEs into the instrument. The GenePOC instrument consists of a rotor to spin the PIEs, temperature control, fluorescence detection, a tactile user-friendly interface, two barcode readers, and integrated firmware and software to deliver results to the user. The PIE is a closed system that prevents the risk of contamination. An unformed (soft or liquid) stool specimen is collected using standard stool collection device. Using a disposable 5µL inoculating loop (transfer loop) dipped into the homogenized stool specimen, stool material is transferred into SBT and vortexed. Sample is then transferred to the GenePOC CDiff PIE. The GenePOC CDiff PIE is then automatically processed by the GenePOC Instrument. On completion of a run, the user removes the processed PIEs from the instrument and discards them according to local biological waste management procedures. One GenePOC instrument per site will be allocated. The purpose of the clinical investigation is to enroll sufficient specimens from up to 7 Clinical Centers to obtain a total of 150 specimens positive for CDiff based on the Reference Method final result. Subject Informed consent is not required for this clinical trial as the testing will be performed on excess de-identified specimens only.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Unformed Stool specimens from patients suspected of having CDI for whom diagnostic tests are indicated and ordered;
- •At least 1.25mL of unformed stool specimen (defined as specimen assuming the shape of its container);
- •Only one (1) specimen per patient will be included in the study;
- •Materials use within their expiration date;
- •Transport, storage times, and conditions (e.g. room temperature and/or refrigerated) within requested indications.
Exclusion Criteria
- •Specimens from patients for whom CDI diagnostic tests have not been ordered;
- •Transport and storage times and conditions that exceed these Study Protocol requirements;
- •Formed or hard stool specimens or rectal swabs.
Outcomes
Primary Outcomes
Performance Characteristics : Clinical Sensitivity (True Positive Rate) and Clinical Specificity (True Negative Rate) in Comparison to the Reference Method
Time Frame: At the time of the results with Reference Method is confirmed, up to 3 months
To establish the performance characteristics of the GenePOC CDiff System for its use in determining the presence of CDiff in liquid/unformed stool specimen obtained from patients suspected of having C. difficile infection (CDI). Sensitivity will be established as the proportion of positives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method. Specificity will be established as the proportion of negatives that are correctly identified by the GenePOC CDiff System, when compared to the Reference Method.
Secondary Outcomes
- Positive and Negative Predictive Values (PPV and NPV)(At the time of the results with Reference Method is confirmed, up to 3 months)
- Unresolved Sample Results(At the time of the results with Reference Method is confirmed, up to 3 months)
- Indeterminate Sample Results(At the time of the results with Reference Method is confirmed, up to 3 months)